19 General introduction 1 REFERENCES 1. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The International Glossary on Infertility and Fertility Care, 2017. Hum Reprod. 2017;32(9):1786801. 2. WHO. International Classification of Diseases. 2018. 3. Mascarenhas MN, Flaxman SR, Boerma T, Vanderpoel S, Stevens GA. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. 4. Thoma ME, McLain AC, Louis JF, King RB, Trumble AC, Sundaram R, et al. Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertil Steril. 2013;99(5):1324-31 e1. 5. Lancet T. Global Burden of Disease: Global Burden of Disease; [Available from: https://www. thelancet.com/gbd/about. 6. Sun H, Gong TT, Jiang, Y.T., Zhang S, Zhao YH, et al. Global, regional, and national prevalences and disability-adjusted life-yearrsr for infertility in 195 countries and territorries, 1990-2017: results froom a global burden of disease study, 2017. AGING. 2019;11:10952-91. 7. RCOG. Fertility problems: asstessment and treatment. London; 2013. Contract No.: CG 156. 8. ACOG. Infertility workup for the women’s health specialist. ACOG Committee Opinion No. 781. 2019. 9. Bhattacharya S, Porter M, Amalraj E, Templeton A, Hamilton M, Lee AJ, et al. The epidemiology of infertility in the North East of Scotland. Hum Reprod. 2009;24(12):3096-107. 10. WHO. WHO Laboratory manual for the examination of human semen and sperm-cervical mucus interaction. Geneva (Switzerland); 2010. 11. Rantsi T, Land JA, Joki-Korpela P, Ouburg S, Hokynar K, Paavonen J, et al. Predictive Values of Serum Chlamydia trachomatis TroA and HtrA IgG Antibodies as Markers of Persistent Infection in the Detection of Pelvic Adhesions and Tubal Occlusion. Microorganisms. 2019;7(10). 12. Kosseim M, Brunham RC. Fallopian tube obstruction as a sequela to Chlamydia trachomatis infection. Eur J Clin Microbiol. 1986;5(5):584-90. 13. Luttjeboer FY, Verhoeve HR, van Dessel HJ, van der Veen F, Mol BW, Coppus SF. The value of medical history taking as risk indicator for tuboperitoneal pathology: a systematic review. BJOG. 2009;116(5):612-25. 14. Rubin IC. The nonoperative determination of patency of Fallopian tubes. JAMA. 1920;75:6617. 15. Ross JW. Transuterine tubal insufflation (Rubin’s method). J Natl Med Assoc. 1955;47:165-7. 16. Guideline-Fertility workup: Dutch Society of Obstetrics and Gynaecology; 2015 [Available from: https://richtlijnendatabase.nl/richtlijn/orienterend_fertiliteitsonderzoek_ofo/startpagina_orienterend_fertilitietsonderzoek.html. 17. Gordts S, Campo R, Rombauts L, Brosens I. Transvaginal hydrolaparoscopy as an outpatient procedure for infertility investigation. Hum Reprod. 1998;13:99-103. 18. Bergin JHE. The advantages and disadvantages of salpingography with particular reference to the use of dioddone viscous. Br J Radiol. 1951;24:93-102. 19. Bonnemain B, Guerbet M. The history of Lipiodol (1901-1994) or how a medication may evolve with the times. Rev Hist Pharm Paris. 1995;42:159-70. 20. Schoemaker J. Serial-hysterosalpingography. Amsterdam: Vrije Universiteit; 1973. 21. Perry EB. Uterosalpingography. J Natl Med Assoc. 1935;27:153-8. 22. Barnett E. The clinical value of hysterosalpingography. Clinical Radiology. 1956(3):184-96.
RkJQdWJsaXNoZXIy MTk4NDMw